Commercial Reach in Latin America
Stematix has begun the process of introducing clinic-ready therapies in key bases in Latin America, starting in Argentina. A number of the rapidly developing countries in Latin America have begun innovations in healthcare delivery which embrace the full range of regenerative medicine options based on adult stem cell therapies -- ranging from umbilical cord bankin
g to advances in therapies using autologous cord blood, peripheral blood, and bone marrow aspirates. Today, in several Latin American countries, clinical trials conducted to world standards are in progress. This type of activity will lead to significant advances in regenerative medicine delivered to patients using adult stem cells. Stematix believes that several Latin American countries will become leaders in delivery of approved regenerative medicine treatments based on adult stem cells. This will benefit not only their own people with lower cost treatments for diseases now difficult or impossible to cure, but such treatments will be available to patients from outside the region as well. It is in this forward-looking and innovative environment that Stematix is beginning to deliver approved, advanced adult stem cell based regenerative medicine treatments. Our experience in Latin America is that the mainstream medical community operates to a very high standard both of ethics and of medical delivery and embraces a social goal of delivering the best possible medical care to as many people as possible.
02. Stematix Know-How & Technology
Stematix has answered the expressed need for comprehensive commercial solutions that integrate current niche stem cell technologies, services, therapies and research needed to establish world-class stem cell research, banks and clinics. Stematix is interested in licensing a small number of synergistic technologies, which can advance the progress toward fast-tracked, world-class stem cell therapies.
03. Stematix Partner Therapy Clinic Network
Through a public-private partnerships model, Stematix and its partners ensure that their banks and clinics enable rapid, regulated and approved, effective adult stem cell therapy. Thus, Stematix aims to build a growing network of therapy clinics around the world, which will enhance mutual learnings, and industry expertise of all clinics in the Stematix Network. Each clinic may be transformational to medical practice in its region whether it is co-located with a hospital or independent.
04. Post-Natal Stem Cell Cord Products (for Research Markets), Storage and Therapy
Stematix has access to consistent sources of a variety of valuable post-natal adult stem cells, including umbilical cord, umbilical cord blood and placental stem cells. The cells are processed and collected according to rigorous international standards, and are sold for research purposes.
• For more information on available Stematix post-natal stem cell products, please contact info@stematix.com
05. is announcing an initiative to promote regenerative medicine treatments in the field of sports medicine. This initiative will seek to commercialize approved Adult-Stem Cell based therapies for orthopedic treatments. Most competitive athletes, over the course of a long career, experience various types of severe joint, tendon, ligament, or bone pain due to injury and other factors. In many cases, surgery and extensive rehabilitation are the only alternatives. This leads to long periods of recovery, and can incur huge financial costs. However, new breakthroughs in the field of Regenerative Medicine, most notably Adult-Stem Cell treatments, are now offering a viable alternative to athletes. Treatments using a patient’s own bone-marrow derived stem cells can rapidly speed up the recovery process, and in some cases eliminate the need for surgery altogether. will be working with various sports teams and insurance carriers to cover the costs of providing approved adult-stem cell therapies to athletes, which will enable them to return to the sports field faster, and will also reduce the long-term costs of providers.
